NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology firm on a mission to rework affected person outcomes by growing rapid-acting, sturdy and handy psychological well being therapies, as we speak introduced it has obtained the Silver Award in OVID Well being’s 2026 Affected person Participant Index (PPI), in collaboration with the Psychedelic Participant Advocacy Community (PsyPAN), in recognition of their joint efforts to strengthen participant partnership in psychedelic medical analysis. The popularity highlights AtaiBeckley’s multiyear collaboration with PsyPAN to combine the lived experiences of medical trial individuals into the accountable improvement of novel psychological well being therapies and amplify these learnings throughout the sector.
In 2023, Beckley Psytech Restricted (now a part of AtaiBeckley) and PsyPAN co-designed a sequence of qualitative workshops exploring the participant expertise earlier than, throughout, and after medical trial participation. Insights from these workshops had been synthesized into the publicly out there white paper, “The Participants in Their Own Words,” and co-presented on the Interdisciplinary Convention on Psychedelic Analysis (ICPR) in 2024. In recognition of the learnings, Beckley Psytech Restricted then offered PsyPAN with an unrestricted grant enabling a 12-month unbiased peer-support pilot program in 2025. This system was open to UK individuals from any psychedelic medical trial, no matter sponsor.
Since its inception, the partnership has expanded to incorporate worldwide affected person advocacy organizations and educational collaborators at King’s Faculty London and the College of Exeter. Commenting on the partnership, the Psychedelic Participant Advocacy Community mentioned: “PsyPAN’s partnership with AtaiBeckley demonstrates the value of meaningful collaboration among patient communities, researchers, and organizations working in psychedelic science. Former trial participants bring essential lived experience expertise that helps ensure research and treatment development remain ethical, safe, and responsive to those most affected. By piloting peer support, and embedding transparency and participant voice into this partnership, AtaiBeckley has enabled us to make a genuine, lasting impact in the field. We look forward to continuing this work together as psychedelic medicine evolves.”
Kevin Craig, Chief Medical Officer at AtaiBeckley, additionally mentioned: “As novel mental health interventions move through clinical development, understanding participant insight is critical to ensuring they can be responsibly translated into practice. Our collaboration with PsyPAN demonstrates how participant voice can strengthen both the science and participant’s experience of clinical research. We are proud to see this approach recognized as part of the 2026 Patient Participant Index, which includes global biopharmaceutical organizations and highlights the increasing importance of patient partnership standards across healthcare innovation. We also thank PsyPAN for their continued partnership.”
About AtaiBeckley Inc.AtaiBeckley is a clinical-stage biotechnology firm on a mission to rework affected person outcomes by growing rapid-acting, sturdy, and handy psychological well being therapies. AtaiBeckley’s pipeline of novel therapies contains BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant despair (TRD), VLS-01 (DMT buccal movie) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiousness dysfunction. BPL-003 is in Section 3 planning, VLS-01 and EMP-01 are in Section 2 medical improvement. The Firm can also be advancing a drug discovery program to determine novel, non-hallucinogenic 5-HT2AR agonists for opioid use dysfunction and TRD. These packages purpose to create breakthroughs in psychological well being by means of transformative interventional psychiatry therapies that may combine seamlessly into healthcare methods.
More Read
For the most recent updates and to study extra concerning the AtaiBeckley mission, go to www.ataibeckley.com or observe the Firm on LinkedIn and on X.
